- Insider Monkey
Does 10x Genomics (TXG) Have a Strong Growth Opportunity Ahead?
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The Small Company Fund returned 0.48%, significantly underperforming the Russell 2000 Growth index’s 7.58% return. Following the release of the inflation report in February, the […]
- PR Newswire
10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel. The new panel features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation and industry-leading speed and throughput.
- Simply Wall St.
We Think Some Shareholders May Hesitate To Increase 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation
Key Insights 10x Genomics to hold its Annual General Meeting on 11th of June Total pay for CEO Serge Saxonov includes...
